Thus, our results demonstrate that TCL1A is a client protein of HSP90A, and that HSP90A’s direct binding leads to it stabilization, thereby contributing to AKT activation in NANOGhigh tumor cells. This evidence concerns the gene TCL1A and neoplasm.